With First IND, Recursion Readies Its AI, Experimental Biology Approach For The Clinic

Emerging Company Profile: With an early focus on rare, monogenic diseases, Recursion believes its platform combining artificial intelligence and experimental biology can be applied to any disease that can be modeled on a cellular level.